Literature DB >> 28537342

Assessing the Risk of Sarcopenia in the Elderly: The Mini Sarcopenia Risk Assessment (MSRA) Questionnaire.

A P Rossi1, R Micciolo, S Rubele, F Fantin, C Caliari, E Zoico, G Mazzali, E Ferrari, S Volpato, M Zamboni.   

Abstract

OBJECTIVES: to validate the MSRA questionnaire proposed as prescreening tool for sarcopenia, in a population of community-dwelling elderly subjects.
DESIGN: observational study.
SETTING: community dwelling elderly subjects. PARTICIPANTS: 274 community dwelling elderly subjects, 177 women and 97 men, aged 66-78 years. MEASUREMENTS: Based on EWGSOP diagnostic criteria subjects were classified as sarcopenic and non-sarcopenic. The Mini Sarcopenia Risk Assessment (MSRA) questionnaire, is composed of seven questions and investigates anamnestic and nutritional characteristics related to risk of sarcopenia onset (age, protein and dairy products consumption, number of meals per day, physical activity level, number of hospitalizations and weight loss in the last year).
RESULTS: 33.5% of the study population, were classified as sarcopenic. With the 7-item MSRA score, subjects with a score of 30 or less, had a 4-fold greater risk of being sarcopenic than subjects with a score higher than 30 (OR:4.20;95% CI:2.26-8.06); area under the ROC curve was 0.786 (95% CI:0.725-0.847). In a logistic regression, considering as dependent variable the probability of being sarcopenic, and as independent variables the 7 items of the questionnaire, two items (number of meals and milk and dairy products consumption) showed non-significant diagnostic power. A 5-item score was then derived and the area under the ROC curve was 0.789 (95% IC:0.728-0.851). Taking into account the cost of false positive and false negative costs and the prevalence of sarcopenia, the "optimal" threshold of the original MSRA score (based on 7 items) is 30, with a sensitivity of 0.804 and a specificity of 0.505, while the "optimal" threshold of the MSRA score based on 5 items, is 45, with a sensitivity of 0.804 and a specificity of 0.604.
CONCLUSION: this preliminary study shows that the MSRA questionnaire is predictive of sarcopenia and can be suggested as prescreening instrument to detect this condition. The use of a short form of the MSRA questionnaire improves the capacity to identify sarcopenic subjects.

Entities:  

Keywords:  Sarcopenia; muscle strength; risk factor assessment

Mesh:

Year:  2017        PMID: 28537342     DOI: 10.1007/s12603-017-0921-4

Source DB:  PubMed          Journal:  J Nutr Health Aging        ISSN: 1279-7707            Impact factor:   4.075


  24 in total

1.  Effect of 10 days of bed rest on skeletal muscle in healthy older adults.

Authors:  Patrick Kortebein; Arny Ferrando; Juan Lombeida; Robert Wolfe; William J Evans
Journal:  JAMA       Date:  2007-04-25       Impact factor: 56.272

Review 2.  Sarcopenic Obesity: An Appraisal of the Current Status of Knowledge and Management in Elderly People.

Authors:  S Molino; M Dossena; D Buonocore; M Verri
Journal:  J Nutr Health Aging       Date:  2016       Impact factor: 4.075

3.  Identifying sarcopenia in acute care setting patients.

Authors:  Andrea P Rossi; Francesco Fantin; Rocco Micciolo; Monica Bertocchi; Paolo Bertassello; Valeria Zanandrea; Alessandra Zivelonghi; Luisa Bissoli; Mauro Zamboni
Journal:  J Am Med Dir Assoc       Date:  2014-02-06       Impact factor: 4.669

Review 4.  Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine.

Authors:  M H Zweig; G Campbell
Journal:  Clin Chem       Date:  1993-04       Impact factor: 8.327

5.  Prevalence and risk factors of sarcopenia among nursing home older residents.

Authors:  Francesco Landi; Rosa Liperoti; Domenico Fusco; Simona Mastropaolo; Davide Quattrociocchi; Anna Proia; Andrea Russo; Roberto Bernabei; Graziano Onder
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2011-03-10       Impact factor: 6.053

6.  Skeletal muscle loss: cachexia, sarcopenia, and inactivity.

Authors:  William J Evans
Journal:  Am J Clin Nutr       Date:  2010-02-17       Impact factor: 7.045

7.  The healthcare costs of sarcopenia in the United States.

Authors:  Ian Janssen; Donald S Shepard; Peter T Katzmarzyk; Ronenn Roubenoff
Journal:  J Am Geriatr Soc       Date:  2004-01       Impact factor: 5.562

8.  Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People.

Authors:  Alfonso J Cruz-Jentoft; Jean Pierre Baeyens; Jürgen M Bauer; Yves Boirie; Tommy Cederholm; Francesco Landi; Finbarr C Martin; Jean-Pierre Michel; Yves Rolland; Stéphane M Schneider; Eva Topinková; Maurits Vandewoude; Mauro Zamboni
Journal:  Age Ageing       Date:  2010-04-13       Impact factor: 10.668

9.  Relationship between protein intake and dynapenia in postmenopausal women.

Authors:  M E Filion; S Barbat-Artigas; S Dupontgand; A Fex; A D Karelis; M Aubertin-Leheudre
Journal:  J Nutr Health Aging       Date:  2012-07       Impact factor: 4.075

Review 10.  Epidemiology and consequences of sarcopenia.

Authors:  G Abellan van Kan
Journal:  J Nutr Health Aging       Date:  2009-10       Impact factor: 4.075

View more
  18 in total

1.  Editorial: Screening for Sarcopenia.

Authors:  J E Morley; A M Sanford
Journal:  J Nutr Health Aging       Date:  2019       Impact factor: 4.075

2.  Oculomics for sarcopenia prediction: a machine learning approach toward predictive, preventive, and personalized medicine.

Authors:  Bo Ram Kim; Tae Keun Yoo; Hong Kyu Kim; Ik Hee Ryu; Jin Kuk Kim; In Sik Lee; Jung Soo Kim; Dong-Hyeok Shin; Young-Sang Kim; Bom Taeck Kim
Journal:  EPMA J       Date:  2022-08-08       Impact factor: 8.836

3.  Differences in the Prevalence of Sarcopenia in Community-Dwelling, Nursing Home and Hospitalized Individuals. A Systematic Review and Meta-Analysis.

Authors:  S K Papadopoulou; P Tsintavis; P Potsaki; D Papandreou
Journal:  J Nutr Health Aging       Date:  2020       Impact factor: 4.075

4.  Sarcopenia screening strategies in older people: a cost effectiveness analysis in Iran.

Authors:  Ali Darvishi; Mohsen Rezaei Hemami; Gita Shafiee; Rajabali Daroudi; Mahsa Mohseni; Farkhondeh Hosseini Shekarabi; Ramin Heshmat
Journal:  BMC Public Health       Date:  2021-05-17       Impact factor: 3.295

Review 5.  Screening Tools for Sarcopenia.

Authors:  Hiroki Nishikawa; Akira Asai; Shinya Fukunishi; Toshihisa Takeuchi; Masahiro Goto; Takeshi Ogura; Shiro Nakamura; Kazuki Kakimoto; Takako Miyazaki; Shuhei Nishiguchi; Kazuhide Higuchi
Journal:  In Vivo       Date:  2021 Nov-Dec       Impact factor: 2.155

6.  Validation of the Chinese version of the Mini Sarcopenia Risk Assessment questionnaire in community-dwelling older adults.

Authors:  Ming Yang; Xiaoyi Hu; Lingling Xie; Luoying Zhang; Jie Zhou; Jing Lin; Ying Wang; Yaqi Li; Zengli Han; Daipei Zhang; Yun Zuo; Ying Li; Linna Wu
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.817

7.  Comparison of Diagnostic Performance of SARC-F and Its Two Modified Versions (SARC-CalF and SARC-F+EBM) in Community-Dwelling Older Adults from Poland.

Authors:  Roma Krzymińska-Siemaszko; Ewa Deskur-Śmielecka; Aleksandra Kaluźniak-Szymanowska; Marta Lewandowicz; Katarzyna Wieczorowska-Tobis
Journal:  Clin Interv Aging       Date:  2020-04-28       Impact factor: 4.458

8.  Comparison of four sarcopenia screening questionnaires in community-dwelling older adults from Poland using six sets of international diagnostic criteria of sarcopenia.

Authors:  Roma Krzymińska-Siemaszko; Sławomir Tobis; Marta Lewandowicz; Katarzyna Wieczorowska-Tobis
Journal:  PLoS One       Date:  2020-04-20       Impact factor: 3.240

9.  SARC-F for sarcopenia screening in community-dwelling older adults: Are 3 items enough?

Authors:  Ming Yang; Xiaoyi Hu; Lingling Xie; Luoying Zhang; Jie Zhou; Jing Lin; Ying Wang; Yaqi Li; Zengli Han; Daipei Zhang; Yun Zuo; Ying Li; Linna Wu
Journal:  Medicine (Baltimore)       Date:  2018-07       Impact factor: 1.889

Review 10.  Sarcopenia: A Contemporary Health Problem among Older Adult Populations.

Authors:  Sousana K Papadopoulou
Journal:  Nutrients       Date:  2020-05-01       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.